[1]
Agarwala A, Goldberg AC. Bempedoic acid: a promising novel agent for LDL-C lowering. Future cardiology. 2020 Sep:16(5):361-371. doi: 10.2217/fca-2020-0016. Epub 2020 May 28
[PubMed PMID: 32463301]
[2]
Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Journal of the American College of Cardiology. 2013 Sep 24:62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13
[PubMed PMID: 23770179]
Level 1 (high-level) evidence
[3]
Marrs JC, Anderson SL. Bempedoic acid for the treatment of dyslipidemia. Drugs in context. 2020:9():. doi: 10.7573/dic.2020-6-5. Epub 2020 Aug 24
[PubMed PMID: 32922503]
[4]
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ, CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England journal of medicine. 2023 Apr 13:388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4
[PubMed PMID: 36876740]
[5]
Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert opinion on pharmacotherapy. 2019 May:20(7):791-803. doi: 10.1080/14656566.2019.1583209. Epub 2019 Feb 27
[PubMed PMID: 30810432]
Level 3 (low-level) evidence
[6]
Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, Mearelli F, Di Girolamo FG. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Frontiers in cardiovascular medicine. 2022:9():1028355. doi: 10.3389/fcvm.2022.1028355. Epub 2022 Oct 28
[PubMed PMID: 36386319]
[7]
Keaney JF Jr. Bempedoic Acid and the Prevention of Cardiovascular Disease. The New England journal of medicine. 2023 Apr 13:388(15):1427-1430. doi: 10.1056/NEJMe2300793. Epub 2023 Mar 4
[PubMed PMID: 36876758]
[8]
Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic Acid: for Whom and When. Current atherosclerosis reports. 2022 Oct:24(10):791-801. doi: 10.1007/s11883-022-01054-2. Epub 2022 Jul 28
[PubMed PMID: 35900636]
[9]
Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, Ginsberg HN, Goldberg IJ, Murad MH, Subramanian S, Tannock LR. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2020 Dec 1:105(12):. pii: dgaa674. doi: 10.1210/clinem/dgaa674. Epub
[PubMed PMID: 32951056]
Level 1 (high-level) evidence
[10]
Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2023 Aug 29:82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20
[PubMed PMID: 37480922]
Level 1 (high-level) evidence
[11]
American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes care. 2024 Jan 1:47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010. Epub
[PubMed PMID: 38078592]
[12]
Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature communications. 2016 Nov 28:7():13457. doi: 10.1038/ncomms13457. Epub 2016 Nov 28
[PubMed PMID: 27892461]
[13]
Abdul-Rahman T, Bukhari SMA, Herrera EC, Awuah WA, Lawrence J, de Andrade H, Patel N, Shah R, Shaikh R, Capriles CAA, Ulusan S, Ahmad S, Corriero AC, Mares AC, Goel A, Hajra A, Bandyopadhyay D, Gupta R. Lipid Lowering Therapy: An Era Beyond Statins. Current problems in cardiology. 2022 Dec:47(12):101342. doi: 10.1016/j.cpcardiol.2022.101342. Epub 2022 Jul 31
[PubMed PMID: 35918009]
[15]
Oliver W, Giugliano RP. Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. Current atherosclerosis reports. 2023 Mar:25(3):85-93. doi: 10.1007/s11883-023-01084-4. Epub 2023 Feb 10
[PubMed PMID: 36763180]
[16]
Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct:277():195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12
[PubMed PMID: 29910030]
Level 1 (high-level) evidence
[17]
Toth PP, Bray S, Villa G, Palagashvili T, Sattar N, Stroes ESG, Worth GM. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association. 2022 Sep 20:11(18):e025551. doi: 10.1161/JAHA.122.025551. Epub 2022 Sep 8
[PubMed PMID: 36073669]
Level 2 (mid-level) evidence
[18]
Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Fácila L, Salgado-Barreira Á, Reyes-Santías F, Romero-Menor C, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Sandin M, Pamias RF, Bañeras J, García PB, Lorenzo MC, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis. Journal of cardiovascular pharmacology. 2023 Jan 1:81(1):70-75. doi: 10.1097/FJC.0000000000001365. Epub 2023 Jan 1
[PubMed PMID: 36219195]
[19]
Amore BM, Sasiela WJ, Ries DK, Tresh P, Emery MG. Pharmacokinetics of bempedoic acid in patients with renal impairment. Clinical and translational science. 2022 Mar:15(3):789-798. doi: 10.1111/cts.13202. Epub 2021 Dec 1
[PubMed PMID: 34800002]
[20]
Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Correction to: Role of Bempedoic Acid in Clinical Practice. Cardiovascular drugs and therapy. 2021 Aug:35(4):865. doi: 10.1007/s10557-021-07188-w. Epub
[PubMed PMID: 33871715]
[21]
Jadhav SB, Crass RL, Chapel S, Kerschnitzki M, Sasiela WJ, Emery MG, Amore BM, Barrett PHR, Watts GF, Catapano AL. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. European heart journal. Cardiovascular pharmacotherapy. 2022 Sep 3:8(6):578-586. doi: 10.1093/ehjcvp/pvab064. Epub
[PubMed PMID: 34448822]
[22]
Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. Journal of clinical pharmacology. 2006 Mar:46(3):328-36
[PubMed PMID: 16490809]
[23]
Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. Journal of clinical pharmacology. 2006 Mar:46(3):321-7
[PubMed PMID: 16490808]
[24]
Bardolia C, Amin NS, Turgeon J. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Frontiers in cardiovascular medicine. 2021:8():789931. doi: 10.3389/fcvm.2021.789931. Epub 2021 Nov 17
[PubMed PMID: 34869702]
[25]
Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Bloedon LT, Sasiela WJ, Ye Z, Ballantyne CM. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of clinical lipidology. 2020 Sep-Oct:14(5):649-659.e6. doi: 10.1016/j.jacl.2020.08.009. Epub 2020 Sep 2
[PubMed PMID: 32980290]
Level 1 (high-level) evidence
[26]
Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA cardiology. 2020 Oct 1:5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314. Epub
[PubMed PMID: 32609313]
Level 1 (high-level) evidence
[27]
Laufs U, Ballantyne CM, Banach M, Bays H, Catapano AL, Duell PB, Goldberg AC, Gotto AM, Leiter LA, Ray KK, Bloedon LT, MacDougall D, Zhang Y, Mancini GBJ. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of clinical lipidology. 2022 May-Jun:16(3):286-297. doi: 10.1016/j.jacl.2022.03.001. Epub 2022 Mar 13
[PubMed PMID: 35346603]
Level 1 (high-level) evidence
[28]
Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ESG, Robinson P, Lei L, Ray KK. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). The American journal of cardiology. 2022 Jul 1:174():1-11. doi: 10.1016/j.amjcard.2022.03.020. Epub 2022 Apr 26
[PubMed PMID: 35483979]
[29]
Lu T, Grewal T. Ezetimibe: An Unusual Suspect in Angioedema. Case reports in medicine. 2020:2020():9309382. doi: 10.1155/2020/9309382. Epub 2020 Feb 27
[PubMed PMID: 32180811]
Level 3 (low-level) evidence
[30]
Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, Zhou L, Fang F. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovascular diabetology. 2020 Aug 12:19(1):128. doi: 10.1186/s12933-020-01101-9. Epub 2020 Aug 12
[PubMed PMID: 32787939]
Level 1 (high-level) evidence
[31]
Yang Y, Lu H, Qu J. Tendon pathology in hypercholesterolaemia patients: Epidemiology, pathogenesis and management. Journal of orthopaedic translation. 2019 Jan:16():14-22. doi: 10.1016/j.jot.2018.07.003. Epub 2018 Aug 6
[PubMed PMID: 30723677]
[32]
Jacomelli I, Monzo L, Panattoni G, Lanzillo C, Rebecchi M, Calò L. Bempedoic acid: what prospective uses? European heart journal supplements : journal of the European Society of Cardiology. 2023 May:25(Suppl C):C109-C111. doi: 10.1093/eurheartjsupp/suad012. Epub 2023 Apr 26
[PubMed PMID: 37125277]
[33]
Bays HE, Baum SJ, Brinton EA, Plutzky J, Hanselman JC, Teng R, Ballantyne CM. Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American journal of preventive cardiology. 2021 Dec:8():100278. doi: 10.1016/j.ajpc.2021.100278. Epub 2021 Oct 4
[PubMed PMID: 34746903]